Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

Overview of attention for article published in Journal of Hematology & Oncology, March 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#2 of 1,274)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 90 news outlets

twitter: 10 X users

Citations

dimensions_citation: 60 Dimensions

Readers on

mendeley: 58 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 60 publications that cite this research output.

60

The most recent citing publications are shown below. View all 60 publications that cite this research output on Dimensions.

Emerging Therapeutics in Chronic Urticaria

Article in Immunology and Allergy Clinics of North America (April 2024)

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Article in Science (February 2024)

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis

Article in Therapeutic Advances in Neurological Disorders (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.